Bausch Health upgraded to overweight from neutral at JPMorgan, price target raised to $38 from $32
The tweet about Bausch Health being upgraded to overweight from neutral and having its price target raised appears to be a neutral statement. It doesn't necessarily reflect a positive or negative emotion towards the market trend. Therefore, the output is 1,